Clinical Trial Update: Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating hypofractionated radiotherapy combined with NALIRIF and a PD-1 antibody for locally recurrent rectal cancer, currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Locally Recurrent Rectal Cancer

Drugs mentioned

• NALIRIF
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Fudan University | Conditions: Locally Recurrent Rectal Cancer | Phase 2 | Status: RECRUITING